Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 16Unknown 4Terminated 3Withdrawn 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 24Myelodysplastic Syndromes 5Leukemia, Biphenotypic, Acute 5Leukemia, Myelomonocytic, Chronic 3Neoplasm, Residual 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Carcinoma, Hepatocellular 2Blast Crisis 2Sarcoma, Myeloid 1Recurrence 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Down Syndrome 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 1Injections 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1Etoposide 1Decitabine 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myelomonocytic, Acute × Idarubicin × Clear all
NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡